Kornimate/medical-research-clean huggingface dataset:
korean registry of thoracic endovascular aortic repair timing for type b aortic dissection (k-team study): a prospective multicenter registry

Conditions: Type B Aortic Dissection

Summary: prospective, single-arm, multi-center registry study a total of 50 subjects with type b aortic dissection who meet all inclusion and exclusion criteria will be included. patients will be treated with tevar using conformable tag endograft (gore). patients will be followed clinically for 12 months after the procedure. ct will be performed at 12 months.


Eligibility criteria:
inclusion criteria: 1. a) in case of acute type b dissection (14 days from first dissection) * maximum aortic diameter \>40 mm or * increase in aortic diameter \>2 mm from baseline b) in case of subacute (15\~90 days) or chronic (90 days \~ 1 year) type b * maximum aortic diameter \>55 mm or * increase in aortic diameter \>4 mm from baseline 2. age 19-80 years. 3. aorta anatomy appropriate for stent graft therapy, 1. proximal landing zone (diameters between 23 and 42 mm) is not aneurysmal, dissected or significantly thrombosed. 2. proximal landing zone length \>20 mm (length from the left subclavian artery origin to the primary intima tear or length from the left common carotid artery origin to the primary intima tear when the left subclavian artery is embolized and possibly revascularized), as measured from the outer curve of the aorta. 4. declaration of voluntary participation in the study with signed informed consent form. exclusion criteria: 1. endorgan ischemia or evidence of malperfusion due to aortic dissection 2. aortic rupture or impeding rupture due to aortic dissection 3. renal dysfunction with serum cr level \>2.0 mg/dl 4. marfan syndrome, loeys-diets, ehlers-danlos syndrome, or other connective tissue diseases 5. uncontrolled active infection or active vasculitis. 6. recent myocardial infarction or cerebrovascular accident within 4 weeks prior to study enrollment. 7. previous thoracic aorta surgery or stent-graft implantation 8. planned concomitant surgical procedures (other than left subclavian artery transposition or bypass) or major surgery within 30 days of study enrolment. 9. women with positive pregnancy test or at child bearing age 10. life expectancy \<1 year due to comorbidity
esp block for postoperative analgesia in urs surgery

Conditions: Analgesia; Postoperative Pain Management; Nephrolithiasis

Summary: the goal of this clinical trial is to determine whether the erector spinae plane (esp) block provides better pain relief after flexible ureterorenoscopy (urs) surgery compared to standard analgesia alone. researchers want to know: does the esp block reduce pain levels in the first 24 hours after surgery? does it lower the need for opioid pain medication? does it reduce the need for additional (rescue) pain treatment? does it decrease the likelihood of postoperative nausea and vomiting (ponv)? participants will be randomly placed into one of two groups: esp block group: participants will receive an esp block using 20 ml of 0.25% bupivacaine under ultrasound guidance before surgery. control group: participants will receive standard pain management without a nerve block. all participants will receive general anesthesia during surgery and multimodal pain management after surgery. researchers will compare pain scores, opioid use, rescue analgesic needs, and the occurrence of nausea and vomiting between the two groups.

intervention group (esp block): patients will receive 20 ml of 0.25% bupivacaine (1:1 diluted with 0.5% bupivacaine) under ultrasound guidance at the t8-t10 level. control group: no block will be performed, and patients will receive standard postoperative multimodal analgesia. procedure description: the esp block will be performed under sterile conditions with a high-frequency linear ultrasound probe. a 100-mm echogenic needle will be inserted in a cephalocaudal direction to deposit the local anesthetic deep to the erector spinae muscle at the transverse process level. the correct spread of the anesthetic will be confirmed via real-time ultrasound imaging. all patients will receive standardized general anesthesia and multimodal analgesia. outcome measures include postoperative pain (nrs), opioid consumption, rescue analgesia requirement, and postoperative nausea and vomiting (ponv).

Eligibility criteria:
inclusion criteria: patients undergoing elective flexible ureterorenoscopy (urs). age: 18-65 years. asa i-ii. willing to participate and provide written informed consent. exclusion criteria: bmi \>35 kg/m². allergy to local anesthetics. coagulation disorders or use of anticoagulants. patients requiring emergency surgery. patients with infection at the esp block site.
evaluation of two pharmacological protocols for pre-emptive analgesia in impacted third molar surgery

Conditions: Pain; Edema; Trismus

Summary: the main aim of the study is to investigate the pre-emptive effect of dexamethasone and diclofenac associated to codeine to prevent the pain, edema and limited mouth opening at the extraction of third molar.

the surgery of third molar is usually associated with important post-surgical sequelae. the damage caused to tissue and bone may result in considerable pain, edema and trismus. the symptoms start gradually, peaking in 2 days after the extraction. the use of medications such as dexamethasone and diclofenac associated to codeine may support the prevention of post-surgical pain. this clinical trial aim compare the the pre-emptive effect of dexamethasone and diclofenac associated to codeine to prevent the pain, edema and limited mouth opening at the extraction of third molar.

Eligibility criteria:
inclusion criteria: * patients with indication of asymptomatic bilateral extractions of lower third molars; * aged 18 years or older; * have a good health and no disease; exclusion criteria: * patients with history of any medication treatment within 15 days before the beginning of the research, history of allergy to the drugs, substances or materials used in this study, pregnancy or lactation.

Keywords: pain measurement edema trismus
acceptability in dialogues with the robot ebo

Conditions: Nervous System Diseases

Summary: this is a descriptive observational study (first results cross-sectional study, second results longitudinal study). the participants of the study will be exposed to a dialogue with the robot ebo. the user and the therapist's acceptability of the robot, the robot-user interaction during the conversation and the conversation parameters will be assessed.

this is a descriptive observational study (first results cross-sectional study, second results longitudinal study). the participants of the study will be exposed to a dialogue with the robot ebo. the user and the therapist's acceptability of the robot will be measure. also the robot-user interaction during the conversation and the conversation parameters will be assessed. the assessements will be done at week 0 and at week 3. during weeks 1 and 2 the robot will be present in the therapeutic activities of the center.

Eligibility criteria:
inclusion criteria: * users of socio-health centers in extremadura (spain). * patients with neurological pathology diagnosed by a specialist doctor. * over 65 years of age * minimental state examination with a score greater than or equal to 21 (mild-moderate cognitive impairment). exclusion criteria: * severe cognitive impairment * language impairment that prevents the use of verbal communication.

Keywords: nervous system diseases acceptability robot
effect of colloid versus crystalloid on coagulation in elective urological surgery

Conditions: Disorders of Coagulation

Summary: the purpose of this study is to investigate the effect of thin fluid with starch versus thin fluid without starch on coagulation in elective surgery when the patient is normovolæmic during operation.

the primary goal is to register coagulation on basis of blood samples inclusive thromboelastography results. the secondary goal is to register blood loss and use of blood products during operation. the trial concerns 40 patients.

Eligibility criteria:
inclusion criteria: * patient older than 18 years. * indication for elective surgery with removal of the urine bladder. * patient without anticoagulative, acethylsalisylsyre or nsaid medicine during the last 5 days,if using. exclusion criteria: * cerebral haemorrhage * renal insufficiency demanding dialysis * manifest cardiac and hepatic insufficiency * disturbance in coagulation * hypernatriæmi * hyperchloræmi * pregnant or nursing * allergic to hydroxyethylstarch * participating in another trial-if interferring the present trial * incapable of managing his own affairs.
health coaching as a tool for improving medication adherence in adult patients with inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: inflammatory bowel disease (ibd) including crohn's disease (cd) and ulcerative colitis (uc) is a chronic idiopathic intestinal disorder involving the interplay of environmental, immunomodulatory and genetic causative factors. treatment for ibd is multimodal and includes lifestyle modification, chronic pharmacotherapy and surgery. given the need for chronic pharmacotherapy, medication adherence is a crucial therapeutic goal in the management of ibd. in fact, medication non-adherence has been associated with greater risk of relapse and increased healthcare costs. in a previous study, the investigators found clinically identifiable risk factors for non-adherence for self-injectable biologic medications in a population with moderate to severe cd. these risk factors included smoking, prior biologic use, psychiatric history, and current narcotic use. the primary objective of this study is to use a multidisciplinary team approach that implements a targeted coaching intervention to promote behavioral change and improve medication adherence in adult patients with ibd who are at high risk of non-adherence.


Eligibility criteria:
inclusion criteria: * adult patients treated at the inflammatory bowel disease (ibd) clinic at vanderbilt with crohn's disease or ulcerative colitis confirmed by endoscopy or radiology assessment * currently prescribed a biologic agent (self-injectable or infusion) for management of ibd * medication dispensing is documented in patient medical record exclusion criteria: * patients less than 18 years of age * unstable clinical condition (bleeding, infection, intestinal obstruction, etc.) * patients who are required to get biologic medication at a specialty pharmacy outside of vanderbilt university that is not documented in medical record(exclusion due to inability to accurately track prescription refills) * patients with short bowel syndrome, an ostomy, obstructive disease with strictures, history of tuberculosis, hypersensitivity reaction to anti-tnf agent, cancer, renal failure requiring specific treatment such as dialysis * patients with severe psychological comorbidity, defined as reported intent to self-harm or harm others or psychiatric hospitalization in the past year * patients with current alcohol abuse or illegal drug use ascertained by medical history
effects of mac preventive therapy on disease-causing bacteria in hiv-infected patients: a substudy of cpcra 048

Conditions: Mycobacterium Avium-intracellulare Infection; HIV Infections; Pneumococcal Infections

Summary: some people who have taken azithromycin to prevent mac (mycobacterium avium complex, a bacterial infection common in hiv-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the presence of drugs used to kill them). the purpose of this study is to see if people who take azithromycin carry more antibiotic-resistant bacteria than people who have chosen to delay mac preventive therapy. when bacteria like streptococcus (a type of bacteria that causes pneumonia and meningitis) are frequently exposed to antibiotics, the bacteria can become resistant to the drugs. mac preventive therapy uses antibiotics, but this can make it difficult to treat other infections caused by bacteria that have become resistant in hiv-infected persons. if mac preventive therapy is delayed, streptococcus in the body may be less likely to develop resistance. therefore, if the patient does get a streptococcus infection, it will be easier to treat because it is not resistant to the antibiotics.

streptococcus pneumoniae is a leading cause of bacteremia, pneumonia, meningitis, and otitis media in the united states. prior to 1987, this organism was uniformly susceptible to penicillin; since then, however, increasing numbers of isolates resistant to penicillin, as well as to other common antibiotics, have been identified. frequent exposure to antibiotics has been documented as an important risk factor for the emergence of resistant organisms in hiv-infected patients, who are more likely than uninfected people to be colonized with antibiotic-resistant strains of s. pneumoniae. this substudy is the first to examine the effects of withdrawing or delaying the initiation of prophylaxis (in this case, mac prophylaxis) on the prevalence of antibiotic-resistant pneumococci in a prospective manner. study participants are a subset of those enrolled in the cr-mac protocol (cpcra 048). oropharyngeal swabs are taken at baseline and 4 months after randomization, and are used to isolate s. pneumoniae in culture. these isolates are tested for susceptibility to macrolides, penicillin, cephalosporins, quinolones, and tmp-smx. the rates of pneumococcal colonization at baseline and 4 months after randomization are determined and used to estimate the impact of deferring mac prophylaxis on carriage of antibiotic-resistant s. pneumoniae.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are enrolled in cpcra 048.

Keywords: aids-related opportunistic infections mycobacterium avium-intracellulare infection antibiotics, macrolide azithromycin drug administration schedule drug resistance, microbial carrier state streptococcus pneumoniae
safety of intravenous thrombolysis for wake-up stroke

Conditions: Ischemic Stroke

Summary: the purpose is to demonstrate the safety of intravenous tissue plasminogen activator (iv t-pa) in ischemic stroke patients who present to the emergency department (ed) after awakening with the symptoms of suspected ischemic stroke.

this is an open label, multi-center, safety study of acute treatment with iv alteplase in ischemic stroke patients who wake-up with their symptoms. the primary outcome of this study is the frequency of symptomatic hemorrhagic transformation evident within 24 hours of treatment with iv t-pa. clinical improvement defined as a decrease in the national institutes of health stroke scale (nihss) score at 24 hours, 3 days and 90 days and modified rankin scale (mrs) score at 3 and 90 days. for patients that have computed tomographic angiogram (cta) and computed tomographic perfusion (ctp), the incidence of large vessel occlusion will be quantified.

Eligibility criteria:
inclusion criteria: * suspected acute ischemic stroke that occurred during sleep or patients who wake up with focal neurological symptoms. this includes all patients who were last known to be neurologically normal the night before,but then found upon awakening with stroke deficits. it will be considered that the last known onset time is the time when the patient was last known to be well. * 18 to 80 years old * nihss (national institutes of health stroke scale) ≤25 * blood pressure ≤185 mmhg systolic \& ≤110 mmhg diastolic at the time of enrollment. treatment of higher systolic bp is permitted, prior to enrollment * iv t-pa must be given within 3 hours of awakening from sleep * female patients of child-bearing potential must have a negative pregnancy test prior to enrollment exclusion criteria: * ct exclusion criteria: hypodensity \>1/3 middle cerebral artery (mca) territory on non-contrast cranial ct scan or evidence of intracranial or subarachnoid hemorrhage * prior ischemic stroke within 3 months of the presenting event * history of intracranial hemorrhage * known secured or unsecured cerebral aneurysm or vascular malformation * inability to control systolic bp \> 185 mmhg or diastolic bp \> 110 mmhg with iv anti-hypertensive medications * known coagulopathy or evidence of active bleeding * surgical procedures, biopsy, subclavian venous or arterial puncture, trauma within 14 days of the event * gastrointestinal or genitourinary bleeding within 14 days of the event * treated with iv heparin within the previous 24 hours \& an abnormal (partial thromboplastin time) ptt * oral anticoagulants \& an (international normalized ratio) inr \>1.7 * platelet count \<100,000 * venous glucose either \ 450 * any patient who qualifies for this protocol should not be treated with (intra-arterial therapy) iat if the treating physician believes a patient should undergo iat, those patients should be identified a priori and not enrolled into this protocol

Keywords: wake-up stroke ischemic stroke ischemic stroke patients who wake-up with their symptoms
oocyte freezing for fertility preservation in benign ovarian tumors

Conditions: Endometriosis; Dermoid Cyst; Mucinous Cyst

Summary: benign ovarian cysts are frequent during women's life. they are diagnosed with pelvic pain or fortuitously during an ultra-sonographic exam. in case of persistence,a surgery will be necessary to identify the nature of the cyst and assess its benignity. in some case, cysts are recurrent and multiple surgeries are needed leading to a significant risk of ovarian damage by follicular depletion. oocyte cryopreservation is no longer considered as an experimental technique of fertility preservation since 2013 as it has been recognized to be efficient and safe. according to reproductive medicine scientific committees and the french ethic law, fertility preservation has to be proposed in every situation of infertility risk. to date, there is no cohort study dedicated to fertility preservation by oocyte freezing in this specific subgroup of patients. the purpose of the study is to prospectively evaluate the oocyte number and quality after controlled ovarian hyperstimulation in patients with recurrent ovarian cysts.


Eligibility criteria:
inclusion criteria: * women with benign ovarian tumor with high risk of recurrence, i-e, endometrioma, dermoid cysts or mucinous cysts. * women with previous surgery and/or high risk of ovarian damage: bilateral cysts, cyst diameter higher than 5 cms * having a social insurance * able to give an informed consent exclusion criteria: * borderline tumors * undetectable amh levels * personal history of thrombo-embolic events * pregnancy

Keywords: oocyte freezing fertility preservation ovarian cysts benign ovarian tumor endometrioma
effects of saffron on mild to moderate generalized anxiety disorder (gad)

Conditions: Patients With Mild to Moderate GAD

Summary: anxiety disorder is one of the major public health problems worldwide. 25% of people experience anxiety disorders throughout life. generalized anxiety disorder (gad) is known as the most prevalent anxiety disorder. saffron has previously approved as an effective adjuvant therapy in depression and might alleviate gad symptoms.since up to the best of our knowledge no human studies have assessed the therapeutic effect of saffron as an adjuvant therapy in gad patients, therefore, this study is planned to evaluatethe effect of saffron (crocus satious l.) in the treatment of mild to moderate generalized anxiety disorder:


Eligibility criteria:
inclusion criteria: * patients who diagnosed with gad according to dsm-v criteria, hamilton score of 18-25 exclusion criteria: * pregnancy and lactation * receiving antipsychotic medications in a month prior to the recruitment * suffered from other psychological disorders (e.g. bipolar disorder, schizophrenia, mood disorders), and drug abuse
melatonin adolescent research study

Conditions: Sleep Disorders in Children

Summary: the present study will use a within-person, randomized cross-over experimental design to test the effects of exogenous melatonin supplementation on the sleep and daytime functioning of typically developing adolescents with short or disrupted sleep of behavioral origins (i.e., difficulty falling asleep, staying asleep, or premature waking resulting in short or disrupted sleep not attributed to an organic sleep condition).


Eligibility criteria:
inclusion criteria: * self-identified sleep difficulties (e.g., difficulty falling asleep, staying asleep, or premature waking resulting in short or disrupted sleep). * ages 13 to 17 years old * able to understand, read, and write in english * melatonin naive exclusion criteria: * obesity * use of psychiatric medication * drug(s), or supplements known to affect sleep * history of head injury or concussion with loss of consciousness \>1 minute * daily consumption of \>1 caffeinated beverage * risk for any organic sleep disorder (e.g., obstructive sleep apnea, restless leg syndrome)

Keywords: melatonin sleep disturbance adolescents daytime functioning
virtual reality effects on functional capacity and quality of life of people with parkinson's disease

Conditions: Parkinson Disease

Summary: introduction: parkinson's disease (pd) is a progressive neurodegenerative disorder of dopaminergic neurons that can cause some mobility limitations and it has association with quality of life (qol) in patients with pd. virtual reality (vr) has been used to treat of these patients objective: evaluate the functional capacity and qol of individuals with pd using vr with x-box kinect®. methods: were selected 20 individuals classified as stages 1-3, aged 50-75 years. they were divided by lot into two groups (control and experimental) with ten patients in each. the group (cg) treated with exercises (conventional therapy) during five-week, with two sessions per week lasting 60 minutes, while the experimental group (eg) spent half the time with conventional physical therapy and other half of time in virtual rehabilitation (vr). subjects were evaluated before and after treatment using the following scales: unified parkinson's disease rating scale and parkinson's disease questionnaire .


Eligibility criteria:
inclusion criteria: * patients with clinical diagnosis of idiopathic parkinson's disease * male and female * stage 1-3 of the hoehn and yahr scale. exclusion criteria: * have other neurological diseases * they have decompensated systemic diseases * musculoskeletal changes that prevent the achievement of movements * with lowering of the cognitive level assessed using the minimental state examination with cutoff point according to education * with respiratory impairment * with medical restrictions for performing exercises * in physical therapy, occupational therapy service for 3 months or more;